JP2023546536A5 - - Google Patents
Info
- Publication number
- JP2023546536A5 JP2023546536A5 JP2023547328A JP2023547328A JP2023546536A5 JP 2023546536 A5 JP2023546536 A5 JP 2023546536A5 JP 2023547328 A JP2023547328 A JP 2023547328A JP 2023547328 A JP2023547328 A JP 2023547328A JP 2023546536 A5 JP2023546536 A5 JP 2023546536A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- pharmaceutical composition
- dose
- fibrosis
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063091128P | 2020-10-13 | 2020-10-13 | |
| US63/091,128 | 2020-10-13 | ||
| PCT/US2021/054713 WO2022081661A1 (en) | 2020-10-13 | 2021-10-13 | Methods of treating fibrosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023546536A JP2023546536A (ja) | 2023-11-02 |
| JP2023546536A5 true JP2023546536A5 (https=) | 2024-11-14 |
Family
ID=81209448
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023547328A Pending JP2023546536A (ja) | 2020-10-13 | 2021-10-13 | 線維症を処置する方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (4) | US11628167B2 (https=) |
| EP (1) | EP4229828A4 (https=) |
| JP (1) | JP2023546536A (https=) |
| KR (1) | KR20230107568A (https=) |
| CN (1) | CN116349204A (https=) |
| AU (1) | AU2021360767A1 (https=) |
| CA (1) | CA3198661A1 (https=) |
| WO (1) | WO2022081661A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12605377B2 (en) | 2020-10-13 | 2026-04-21 | Endeavor Biomedicines, Inc. | Methods of treating fibrosis |
| JP2023546536A (ja) | 2020-10-13 | 2023-11-02 | エンデバー バイオメディシンズ， インコーポレイテッド | 線維症を処置する方法 |
| AU2024230449A1 (en) * | 2023-02-28 | 2025-09-11 | Endeavor Biomedicines, Inc. | Methods of treating fibrosis |
| WO2025188802A1 (en) | 2024-03-05 | 2025-09-12 | Endeavor Biomedicines, Inc. | Methods of improving lung function |
| WO2025189041A1 (en) * | 2024-03-07 | 2025-09-12 | Endeavor Biomedicines, Inc. | Methods of treating fibrosis |
| WO2025242197A1 (zh) * | 2024-05-24 | 2025-11-27 | 成都思倍博医药科技有限公司 | 氘代的Hedgehog通路SMO受体抑制剂 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN148482B (https=) | 1977-06-03 | 1981-03-07 | Pfizer | |
| MY117098A (en) | 1996-01-15 | 2004-05-31 | Janssen Pharmaceutica Nv | Angiogenesis inhibiting pyridazinamines |
| JP5067986B2 (ja) | 1998-04-09 | 2012-11-07 | ジョンズ ホプキンズ ユニヴァーシティー スクール オブ メディシン | ヘッジホッグシグナリング経路の阻害剤としてのステロイドアルカロイド誘導体の使用 |
| ATE283700T1 (de) | 1999-06-08 | 2004-12-15 | Lorantis Ltd | Therapeutische verwendung eines inhibitors des hedgehog signalübertragungsweges |
| EP1496905B1 (en) | 2002-04-22 | 2008-08-13 | Johns Hopkins University School of Medicine | Modulators of hedgehog signaling pathways, compositions and uses related thereto |
| WO2004020599A2 (en) | 2002-08-29 | 2004-03-11 | Curis, Inc. | Hedgehog antagonists, methods and uses related thereto |
| WO2005033288A2 (en) | 2003-09-29 | 2005-04-14 | The Johns Hopkins University | Hedgehog pathway antagonists |
| TW200533356A (en) | 2004-02-24 | 2005-10-16 | Mitsubishi Pharma Corp | Fused pyridazine derivatives |
| WO2006004589A2 (en) | 2004-05-08 | 2006-01-12 | Neurogen Corporation | 3-aryl-5,6-disubstituted pyridazines |
| ES2377430T3 (es) | 2004-09-02 | 2012-03-27 | Genentech, Inc. | Inhibidores piridílicos de la señalización de hedgehog |
| EP1900731A1 (de) | 2006-09-07 | 2008-03-19 | Bayer Schering Pharma Aktiengesellschaft | N-(1-Phthalazin-1-yl-piperidin-4-yl)-amide als EP2-Rezeptor Modulatoren |
| CA2681162C (en) | 2007-03-15 | 2015-11-24 | Novartis Ag | Benzyl and pyridine derivatives as modulators of hedgehog pathway |
| US8153633B2 (en) | 2007-06-25 | 2012-04-10 | Amgen Inc. | Phthalazine compounds, compositions and methods of use |
| US8222251B2 (en) | 2007-09-07 | 2012-07-17 | Amgen Inc. | Pyridopyridazine compounds, compositions and methods of use |
| UA102250C2 (ru) | 2008-04-29 | 2013-06-25 | Эли Лилли Энд Компани | Двухзамещенные фталазины - антагонисты проводящего пути hedgehog |
| US20100041663A1 (en) | 2008-07-18 | 2010-02-18 | Novartis Ag | Organic Compounds as Smo Inhibitors |
| WO2010017240A2 (en) | 2008-08-04 | 2010-02-11 | Amgen Inc. | Aurora kinase modulators and methods of use |
| MX2011004683A (es) | 2008-11-03 | 2011-06-20 | Lilly Co Eli | Antagonistas de la via hedgehog de ftalazina disustituida. |
| BRPI0921777A2 (pt) | 2008-11-17 | 2016-01-12 | Lilly Co Eli | antagonistas da via hedgehog de piridazina tetrassubstituída |
| KR101342184B1 (ko) | 2008-11-17 | 2013-12-19 | 일라이 릴리 앤드 캄파니 | 사치환된 피리다진 헷지호그 경로 길항제 |
| AR077014A1 (es) | 2009-06-19 | 2011-07-27 | Lilly Co Eli | Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer |
| US20110183948A1 (en) | 2010-01-15 | 2011-07-28 | Infinity Pharmaceuticals, Inc. | Treatment of fibrotic conditions using hedgehog inhibitors |
| GB201309508D0 (en) * | 2013-05-28 | 2013-07-10 | Redx Pharma Ltd | Compounds |
| US9970935B2 (en) * | 2014-02-06 | 2018-05-15 | The Brigham And Women's Hospital, Inc. | Uses of GLI1 in detecting tissue fibrosis |
| GB2528298A (en) * | 2014-07-16 | 2016-01-20 | Redx Pharma Plc | Compounds |
| JP2018535238A (ja) | 2015-11-30 | 2018-11-29 | イグナイタ インコーポレイテッド | 局所製剤 |
| EP3536320A4 (en) * | 2016-11-04 | 2020-07-29 | Impact Therapeutics, Inc | APPLICATION OF A HEDGEHOG TRACT INHIBITOR FOR THE TREATMENT OF FIBROTIC DISEASES |
| US11154541B2 (en) | 2018-06-29 | 2021-10-26 | The Trustees Of Indiana University | Methods for treating aortic valve stenosis with a hedgehog pathway inhibitor |
| EP3823618A1 (en) * | 2018-07-19 | 2021-05-26 | Varian Medical Systems, Inc. | Methods of use of ultra-high dose rate radiation and therapeutic agents |
| JP2023546536A (ja) | 2020-10-13 | 2023-11-02 | エンデバー バイオメディシンズ， インコーポレイテッド | 線維症を処置する方法 |
| US12605377B2 (en) | 2020-10-13 | 2026-04-21 | Endeavor Biomedicines, Inc. | Methods of treating fibrosis |
| AU2024230449A1 (en) | 2023-02-28 | 2025-09-11 | Endeavor Biomedicines, Inc. | Methods of treating fibrosis |
-
2021
- 2021-10-13 JP JP2023547328A patent/JP2023546536A/ja active Pending
- 2021-10-13 KR KR1020237015750A patent/KR20230107568A/ko active Pending
- 2021-10-13 CA CA3198661A patent/CA3198661A1/en active Pending
- 2021-10-13 EP EP21880965.5A patent/EP4229828A4/en active Pending
- 2021-10-13 CN CN202180069900.XA patent/CN116349204A/zh active Pending
- 2021-10-13 WO PCT/US2021/054713 patent/WO2022081661A1/en not_active Ceased
- 2021-10-13 AU AU2021360767A patent/AU2021360767A1/en active Pending
-
2022
- 2022-05-03 US US17/735,798 patent/US11628167B2/en active Active
-
2023
- 2023-02-28 US US18/115,593 patent/US12295954B2/en active Active
-
2024
- 2024-06-26 US US18/755,445 patent/US12213974B2/en active Active
-
2025
- 2025-04-11 US US19/177,041 patent/US20250235452A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023546536A5 (https=) | ||
| JP6141958B2 (ja) | 増殖性疾患の治療のための併用療法（ベムラフェニブ及びｍｄｍ２阻害剤） | |
| KR102634247B1 (ko) | 다발성 골수종을 치료하기 위한 약물 병용물 | |
| JP6091593B2 (ja) | 慢性閉塞性肺疾患の急性増悪の治療におけるピラゾール誘導体の使用 | |
| KR20140022048A (ko) | 선택된 환자에서의 피르페니돈 및 항-섬유성 치료제 | |
| JP2019515884A5 (https=) | ||
| JP2013535437A5 (https=) | ||
| JP2004521134A5 (https=) | ||
| JP2007506752A (ja) | 肺動脈高血圧症を治療するための併用療法におけるイロプロスト | |
| EP1358177B1 (en) | Treatment of affective disorders by the combined action of a nicotinic receptor agonist and a monoaminergic substance | |
| JP6145946B2 (ja) | 併用ａｌｓ療法 | |
| JP2019533660A5 (https=) | ||
| WO2011063764A1 (zh) | 阿齐沙坦有机胺盐及其制备方法和用途 | |
| Li et al. | A comparative study of esketamine-propofol and sufentanil-propofol for analgesia and sedation during breast minimally invasive rotary resection with local anesthesia: a randomized double-blind clinical trial | |
| JP2023528896A5 (https=) | ||
| JP2013536206A5 (https=) | ||
| JP2019531286A5 (https=) | ||
| JP2022518788A (ja) | オピオイド鎮痛耐性を治療するためのｍＧｌｕＲ５アンタゴニストの使用 | |
| JP2009510142A (ja) | 急性および慢性肺障害の処置のための可溶性グアニル酸シクラーゼ活性化剤の使用 | |
| JP2020050624A (ja) | 線維症治療用医薬組成物 | |
| JP2021519285A (ja) | ダブラフェニブ、トラメチニブ及びｅｒｋ阻害剤を含む医薬品の三重の組合せ | |
| CN119837862A (zh) | 玛沃谷兰在减少酒精使用或在预防复用酒精中的用途 | |
| JP2003513888A (ja) | 神経疾患治療用医薬品 | |
| JPWO2012060308A1 (ja) | 腎機能障害の予防又は治療に用いる医薬 | |
| JP2024523558A5 (https=) |